We sought to confirm previous finding that MAOB levels are higher in GBM and low-grade astrocytomas than in control brain tissue [14], to shed light as to why MAOB is upregulated in these cancers and to determine if the design and use of MAOB specific prodrugs is an appropriate route for glioma chemotherapy. This evidence concerns the gene MAOB and central nervous system cancer.